These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17324380)

  • 1. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent.
    Sigmond J; Kamphuis JA; Laan AC; Hoebe EK; Bergman AM; Peters GJ
    Biochem Pharmacol; 2007 May; 73(10):1548-57. PubMed ID: 17324380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
    Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells.
    Fritzer-Szekeres M; Salamon A; Grusch M; Horvath Z; Höchtl T; Steinbrugger R; Jäger W; Krupitza G; Elford HL; Szekeres T
    Biochem Pharmacol; 2002 Aug; 64(3):481-5. PubMed ID: 12147300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines.
    Noordhuis P; Kazemier KM; Kasperrs GJ; Peters GJ
    Leuk Res; 1996 Feb; 20(2):127-34. PubMed ID: 8628011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
    Sigmond J; Bergman AM; Leon LG; Loves WJ; Hoebe EK; Peters GJ
    Anticancer Drugs; 2010 Jul; 21(6):591-9. PubMed ID: 20436341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
    Nandy P; Lien EJ; Avramis VI
    Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.
    Rudd SG; Tsesmetzis N; Sanjiv K; Paulin CB; Sandhow L; Kutzner J; Hed Myrberg I; Bunten SS; Axelsson H; Zhang SM; Rasti A; Mäkelä P; Coggins SA; Tao S; Suman S; Branca RM; Mermelekas G; Wiita E; Lee S; Walfridsson J; Schinazi RF; Kim B; Lehtiö J; Rassidakis GZ; Pokrovskaja Tamm K; Warpman-Berglund U; Heyman M; Grandér D; Lehmann S; Lundbäck T; Qian H; Henter JI; Schaller T; Helleday T; Herold N
    EMBO Mol Med; 2020 Mar; 12(3):e10419. PubMed ID: 31950591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
    Braess J; Wegendt C; Jahns-Streubel G; Kern W; Keye S; Unterhalt M; Schleyer E; Hiddemann W
    Br J Haematol; 2000 May; 109(2):388-95. PubMed ID: 10848830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
    Ramilo-Torno LV; Avramis VI
    Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells.
    Chen P; Aimiuwu J; Xie Z; Wei X; Liu S; Klisovic R; Marcucci G; Chan KK
    AAPS J; 2011 Mar; 13(1):131-40. PubMed ID: 21191677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer.
    Tian L; Chen C; Guo Y; Zhang F; Mi J; Feng Q; Lin S; Xi N; Tian J; Yu L; Chen Y; Cao M; Lai C; Fan J; Zhang Y; Chen G
    Neoplasia; 2021 Jul; 23(7):643-652. PubMed ID: 34126361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation.
    Vrana JA; Kramer LB; Saunders AM; Zhang XF; Dent P; Povirk LF; Grant S
    Biochem Pharmacol; 1999 Jul; 58(1):121-31. PubMed ID: 10403525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
    Gandhi V; Estey E; Keating MJ; Chucrallah A; Plunkett W
    Blood; 1996 Jan; 87(1):256-64. PubMed ID: 8547650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.
    Galmarini CM; Clarke ML; Santos CL; Jordheim L; Perigaud C; Gosselin G; Cros E; Mackey JR; Dumontet C
    Int J Cancer; 2003 Oct; 107(1):149-54. PubMed ID: 12925971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.
    Horber DH; Schott H; Schwendener RA
    Cancer Chemother Pharmacol; 1995; 36(6):483-92. PubMed ID: 7554040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular pharmacology of gemcitabine.
    Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
    Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical modulation of Ara-C effects by amidox, an inhibitor of ribonucleotide reductase in HL-60 promyelocytic human leukemia cells.
    Höchtl T; Horvath Z; Bauer W; Karl D; Saiko P; Elford HL; Fritzer-Szekeres M; Szekeres T
    Life Sci; 2004 Jan; 74(9):1071-80. PubMed ID: 14687648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiosemicarbazone derivatives, thiazolyl hydrazones, effectively inhibit leukemic tumor cell growth: Down-regulation of ribonucleotide reductase activity and synergism with arabinofuranosylcytosine.
    Graser-Loescher G; Schoenhuber A; Ciglenec C; Eberl S; Krupitza G; Mader RM; Jadav SS; Jayaprakash V; Fritzer-Szekeres M; Szekeres T; Saiko P
    Food Chem Toxicol; 2017 Oct; 108(Pt A):53-62. PubMed ID: 28716444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome.
    Jiang HY; Hickey RJ; Abdel-Aziz W; Malkas LH
    Cancer Chemother Pharmacol; 2000; 45(4):320-8. PubMed ID: 10755321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.